Grace Therapeutics Inc (GRCE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -7,793 | -6,615 | -4,301 | -3,362 | -9,568 |
| Depreciation Amortization | 7 | 5 | 2 | 2 | 7 |
| Income taxes - deferred | -1,700 | N/A | N/A | N/A | -3,199 |
| Accounts receivable | 106 | 106 | 106 | 106 | 596 |
| Accounts payable and accrued liabilities | 543 | -320 | -356 | 711 | -84 |
| Other Working Capital | 719 | -280 | -213 | 770 | 342 |
| Other Operating Activity | -751 | -70 | -182 | -28 | -2,998 |
| Operating Cash Flow | $-8,869 | $-7,174 | $-4,944 | $-1,801 | $-14,904 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $0 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 4,040 | 4,040 | N/A | N/A | 14,999 |
| Other Financing Activity | -327 | -327 | -327 | -327 | -967 |
| Financing Cash Flow | $3,713 | $3,713 | $-327 | $-327 | $14,032 |
| Beginning Cash Position | 22,133 | 22,133 | 22,133 | 22,133 | 23,005 |
| End Cash Position | 16,977 | 18,672 | 16,862 | 20,005 | 22,133 |
| Net Cash Flow | $-5,156 | $-3,461 | $-5,271 | $-2,128 | $-872 |
| Free Cash Flow | |||||
| Operating Cash Flow | -8,869 | -7,174 | -4,944 | -1,801 | -14,904 |
| Free Cash Flow | -8,869 | -7,174 | -4,944 | -1,801 | -14,904 |